Sam Brusco, Associate Editor03.04.22
Home respiratory care company Inogen has appointed Kristin Caltrider as EVP and chief financial officer (CFO), beginning March 21. She will succeed Mike Sergesketter, who has been interim CFO since December and will remain with Inogen until June 24.
“Kristin is a proven executive who brings deep experience in leading the financial operations of healthcare businesses,” Inogen president and CEO Nabil Shabshab told the press. “She has a clear track record of partnering cross functionally to successfully develop strategic plans and execute against a clear set of financial and business goals to add scale and drive profitable growth. The Board and I are thrilled that she is joining us at such a pivotal time, as we work to continue the transformation of Inogen into a respiratory care medtech leader, with durable performance and profitability.”
“Inogen is on a great trajectory and it’s an exciting time to join the company,” said Caltrider. “Inogen has a wealth of talent and a clear opportunity to build on its strong platform and drive value for patients and investors alike. I look forward to working with the Board, Nabil and the rest of the management team to execute on the strategic plan and work to position the Company for sustainable, long-term growth.”
Shabshab continued, “I want to thank Mike for his steady support during our search process for a CFO—I am grateful for his willingness to come out of retirement to support Inogen and for bringing his experience and discipline to bear which we have benefited from greatly.”
Caltrider most recently served as Quidel’s VP of finance, a role she has held since June 2014. Before that, she spent almost four years at Life Technologies (now Thermo Fisher Scientific), where she held a number of roles.
“Kristin is a proven executive who brings deep experience in leading the financial operations of healthcare businesses,” Inogen president and CEO Nabil Shabshab told the press. “She has a clear track record of partnering cross functionally to successfully develop strategic plans and execute against a clear set of financial and business goals to add scale and drive profitable growth. The Board and I are thrilled that she is joining us at such a pivotal time, as we work to continue the transformation of Inogen into a respiratory care medtech leader, with durable performance and profitability.”
“Inogen is on a great trajectory and it’s an exciting time to join the company,” said Caltrider. “Inogen has a wealth of talent and a clear opportunity to build on its strong platform and drive value for patients and investors alike. I look forward to working with the Board, Nabil and the rest of the management team to execute on the strategic plan and work to position the Company for sustainable, long-term growth.”
Shabshab continued, “I want to thank Mike for his steady support during our search process for a CFO—I am grateful for his willingness to come out of retirement to support Inogen and for bringing his experience and discipline to bear which we have benefited from greatly.”
Caltrider most recently served as Quidel’s VP of finance, a role she has held since June 2014. Before that, she spent almost four years at Life Technologies (now Thermo Fisher Scientific), where she held a number of roles.